biotech / news / / STAT
The pill, dubbed MK 8527, is currently undergoing a pair of late-stage clinical trials.
Merck's experimental HIV prevention pill could be produced for under $5 per patient annually.
KEY POINTS
- The pill, MK 8527, is in late-stage clinical trials with results expected in late 2027.
- Mid-stage results showed MK 8527 can provide PrEP protection within 24 hours of ingestion.
- MK 8527 operates via a novel mechanism distinct from existing HIV prevention drugs.
COMPANIES
Summarized by Newsio from STAT. How we summarize →